Prognosis of patients with T4 prostate carcinoma

International Journal of Urology

Volumn 6, Issue 4, 1999, Pages 192-195

  Furuya, Yuzo ^a,b   Akakura, Koichiro ^a   Ichikawa, Tomohiko ^a   Ito, Haruo ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Endocrine therapy; Prognosis; Prostate carcinoma; T4

Indexed keywords

ANDROGEN; ANTIANDROGEN; CHLORMADINONE ACETATE; FOSFESTROL; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; JAPAN; LIFE EXPECTANCY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; SURVIVAL RATE; TUMOR DIFFERENTIATION; UNIVERSITY HOSPITAL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033506265     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.1999.06447.x     Document Type: Article

References (20)

1. 1 Walsh PC. The natural history of localized prostate cancer: A guide to therapy. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds). Campbell's Urology, 7th edn. WB Saunders Co., Philadelphia, 1998; 2539-46.
2. 2 Porter AT, Littrup P, Grignon D, Forman J, Montie JE. Radiotherapy and cryotherapy for prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds). Campbell's Urology, 7th edn. WB Saunders Co., Philadelphia, 1998; 2605-26.
3. 3 Witjes WPJ, Oosterhof GON, Schaafsma HE, Debruyne FMJ. Current status of neoadjuvant therapy in localized prostate cancer. Prostate 1995; 27: 297-303.
4. 4 Oesterling JE, Andrews PE, Suman VJ, Zincke H, Myers RP. Preoperative androgen deprivation therapy: Artificial lowering of serum prostate specific antigen without downstaging the tumor. J. Urol. 1993; 149: 779-82.
5. 5 Catalona WJ, Scott WW Carcinoma of the prostate. J. Urol. 1978; 119: 1-8.
6. 6 Schulze H, Isaacs JT, Senge T. Inability of complete androgen blockade to increase survival of patients with advanced prostate cancer as compared to standard hormonal therapy. J. Urol. 1987; 137: 909-11.
7. 7 Hermanek P, Hutter RVP, Sobin LH, Wager G, Wittekind Ch (eds). Prostate. In: TNM Atlas, 4th edn. Springer-Verlag, Berlin, 1997; 272-80.
8. 8 Zagars GK. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol. Clin. North Am. 1993; 20: 737-47.
9. 9 Schroder FH. Endocrine treatment of prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds). Campbell's Urology, 7th edn. WB Saunders Co., Philadelphia, 1998; 2627-44.
10. 10 Japanese Urological Association, the Japanese Society of Pathology (eds). General Rule for Clinical and Pathological Studies on Prostatic Cancer, 2nd edn. Kanehara Publishing Co., Tokyo, 1992 (in Japanese).
11. 11 Kuriyama M, Akimoto S, Akaza H et al. Comparison of various assay systems for prostate-specific antigen standardization. Jpn. J. Clin. Oncol. 1992; 22: 393-9.
12. 12 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457-81.
13. 13 Cox DR. Regression models and life tables. J. R. Stat. Soc. 1972; 34: 187-220.
14. 14 Furuya Y, Akimoto S, Akakura K et al. Response of prostate specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. Urol. Int. 1998; 60: 28-32.
15. 15 Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma. Cancer 1997; 79: 1370-80.
16. 16 Crook JM, Bahadur YA, Bociek RG, Perry GA, Robertson SJ, Esche BA. Radiotherapy for localized prostate carcinoma. Cancer 1997; 79: 328-36.
17. 17 Zagars GK, Geara FB, Pollack A, von Eschenbach AC. The T classification of clinically localized prostate cancer. Cancer 1994; 73: 1904-12.
18. 18 Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 1997; 337: 295-300.
19. 19 Fowler JE, Bigler SA, Kolski JM, Yee DT. Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma. Cancer 1998; 82: 1112-17.
20. 20 Pollak A, Zagars GK, Kopplin S. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1995; 32: 13-20.